American Association for Cancer Research

SHERPA: Unknown

People

  1. Hellmann
    Hellmann
  2. Rizvi
    Rizvi
  3. Rudin
    Rudin
  4. Ladanyi
    Ladanyi
  5. Wolchok
    Wolchok
  6. Kris
    Kris
  7. Merghoub
    Merghoub
  8. Riely
    Riely
  9. Plodkowski
    Plodkowski
  10. Arcila
    Arcila

Groups

  1. Department of Medicine (43)
  2. Solid Tumor Oncology Division (43)
  3. Thoracic Oncology (43)
  4. GSK Faculty (18)
  5. Department of Pathology and Laboratory Medicine (14)
  6. Melanoma and Immunotherapeutics Service (12)
  7. Center for Molecular Imaging and Biotechnology (CMIB) (11)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (9)
  9. Epidemiology and Biostatistics (9)
  10. Weinberg Fellows (9)
Search Within
  1. "Matthew Hellmann"
Formats
  1. Meeting Abstract (23)
  2. Journal Article (19)
  3. Review (1)
Groups
  1. Department of Medicine (43)
  2. Solid Tumor Oncology Division (43)
  3. Thoracic Oncology (43)
  4. GSK Faculty (18)
  5. Department of Pathology and Laboratory Medicine (14)
  6. Melanoma and Immunotherapeutics Service (12)

More Groups

People
  1. Matthew Hellmann (43)
  2. Hira Rizvi (12)
  3. Charles Rudin (9)
  4. Jedd Wolchok (8)
  5. Marc Ladanyi (8)
  6. Gregory Riely (7)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (4)
  4. 2021 (7)
  5. 2020 (10)
  6. 2019 (11)

More Years

Publications
  1. Cancer Research (24)
  2. Clinical Cancer Research (19)

Results (43)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Objective analysis and clinical significance of the spatial tumor-infiltrating lymphocyte patterns in non-small cell lung cancer
    Journal Article

    Lopez de Rodas, M.; Wang, Y.; Peng, G.; Gu, J.; Mino-Kenudson, M.; Riess, J. W.; Velcheti, V.; Hellmann, M.; Gainor, J. F.; Zhao, H.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer
    Journal Article

    Thummalapalli, R.; Ricciuti, B.; Bandlamudi, C.; Muldoon, D.; Rizvi, H.; Elkrief, A.; Luo, J.; Alessi, J. V.; Pecci, F.; Lamberti, G.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer
    Meeting Abstract

    Ravi, A.; Gainor, J.; Arniella, M.; Stewart, C.; Freeman, S.; Awad, M. M.; Forde, P.; Anagnostou, V.; Henick, B.; Riess, J. W.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    de Rodas Gregorio, M. L.; Nagineni, V.; Ravi, A.; Datar, I. J.; Mino-Kenudson, M.; Corredor, G.; Barrera, C.; Behlman, L.; Rimm, D. L.; Herbst, R. S.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Widespread hypertranscription in aggressive human cancer
    Meeting Abstract

    Zatzman, M.; Fuligni, F.; Ripsman, R.; Suwal, T.; Edward, L. M.; Denroche, R.; Jang, G. H.; Notta, F.; Gallinger, S.; Selvanathan, S. P.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer
    Journal Article

    Schoenfeld, A. J.; Rizvi, H. A.; Memon, D.; Shaverdian, N.; Bott, M. J.; Sauter, J. L.; Tsai, C. J.; Lihm, J.; Hoyos, D.; Plodkowski, A. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Immunotherapy-mediated thyroid dysfunction: Genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer
    Journal Article

    Luo, J.; Martucci, V. L.; Quandt, Z.; Groha, S.; Murray, M. H.; Lovly, C. M.; Rizvi, H.; Egger, J. V.; Plodkowski, A. J.; Abu-Akeel, M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • The development of an in vivo model of checkpoint acquired resistance, reveals a program of interferon hyperstimulation, resulting in dysregulation of MHC class I, protein translation/trafficking, and other unique pathways, that may be useful for guiding clinical strategy in patients with phenotypic similarities
    Meeting Abstract

    Fromm, G. J.; Memon, D.; de Silva, S.; Yoo, K. J.; Johannes, K.; Shuptrine, C.; Miriyala, J.; Patel, A.; Rangwala, F.; Opheim, Z.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • An SU2C-Mark Foundation Lung collaborative update: Integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance
    Meeting Abstract

    Arniella, M. B.; Ravi, A.; Gainor, J.; Stewart, C.; Freeman, S.; Awad, M.; Forde, P.; Anagnostou, V.; Henick, B.; Riess, J. W.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC
    Meeting Abstract

    Ricciuti, B.; Arbour, K. C.; Mahadevan, N. R.; Alessi, J. V.; Lindsay, J.; Umeton, R.; Sinha, R.; Hoojghan, A.; Vokes, N.; Recondo, G.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: